By Spondylitis Association of America
A phase 3 clinical trial is now recruiting ankylosing spondylitis patients between the ages of 18-99 to participate in a study of an investigational oral medication, Upadacitinib.
April is Spondylitis Awareness Month. Every April since 2009, the Spondylitis Association of America (SAA) observes the month as part of its ongoing efforts to draw national attention to a potentially debilitating disease that is often undiagnosed or misdiagnosed.
Opioids can be a significant source of pain relief for those experiencing moderate to severe ankylosing spondylitis (AS) symptoms who achieve little pain relief from antirheumatic treatments...
What if one morning, your back and every joint in your body ached so badly that you couldn’t walk or stand? What if you had to live with this chronic inflammatory pain every day for years? It’s difficult to imagine, but it is a painful reality for many.
A person’s genetic makeup, including HLA-B27, is thought to make up roughly 90% of the disease risk in ankylosing spondylitis (AS.)1 It’s not surprising then that ethnicity plays a large role in the frequency of AS throughout the world. New research now suggests that ethnicity may also play a role in disease activity and severity.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.